Purpose: The aim of this study was to assess the long-term efficacy of liraglutide on diabetic nephropathy in elderly patients with type 2 diabetes.

Methods: Liraglutide was administrated to elderly patients with poorly controlled type 2 diabetes in Aino Hospital. We recruited and retrospectively reviewed 31 patients who were treated with liraglutide for 5 years (Group L: 7 males/24 females, 75.4±8.1 years old of age, 16 with cerebrovascular and 8 patients with cardiovascular diseases at baseline) and 25 patients who were not treated with liraglutide (Group N, 9 males/16 females, 74.6±11.6 years old of age). Daily dose of liraglutide was 0.9mg except 2 patients (0.6 mg).

Results: After 5 years of treatment, HbA1c, FPG, and 2h-PPG significantly decreased in both groups (7.5±0.4 to 6.8±0.5 vs. 7.4±0.6 to 6.9±0.4%, 138±19 to 120±11 vs. 132±16 to 113±13, 206±31 to 173±18 vs. 186±23 to 163±18mg/dl, respectively(p<0.01)). Triglycerides significantly decreased in Group L but not in Group N. Body mass index (BMI) significantly decreased in Group L but not in Group N (25.5±4.1 to 24.8±3.8 (p<0.05) vs. 24.1±3.8 to 24.8±3.8kg/m2 (NS)). Estimated glomerular filtration ratio (eGFR) significantly increased in Group L but significantly decreased in Group N (45.6±17.8 to 49.9±18.5 (p<0.05) vs. 48.7±18.9 to 46.3±21.7 ml/min/1.73m2 (p<0.05). When results were stratified according to eGFR at baseline in Group L (Group A(n=6): eGFR >60, Group B (n=18): eGFR = 30-60, Group C (n=7): eGFR<30), eGFR level increased in Group B (43.6±7.6 to 50.8±8.2 (p<0.01)) and in Group A (73.0±10.5 to 76.8±11.1 (NS)), but not in Group C(24.0±3.4 to 23.0±6.3 (NS)). No hypoglycemia requiring medical care was observed. During the treatment period, no newly onset cerebro- and cardiovascular disease were observed.

Conclusion: Liraglutide improved glycemic control, lipid profile and BMI of elderly patients with type 2 diabetes. Liraglutide also demonstrated its beneficial effect on renal function.

Disclosure

M. Yoshida: None. A. Yoshida: None. E. Oh: None. N. Yamamoto: None. E. Sasaki: None. A. Saeki: None. S. Yoshida: None. T. Kuzuya: None. N. Ohsawa: None. M. Sugino: None.

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.